Manufacturer
BAXTER AG
Contents
Factor VIII inhibitor bypassing fraction - The presentation 500 U FEIBA contains 500 U factor VIII inhibitor bypassing activity in 200 - 600 mg human plasma protein,
Indication
Hemophilia A and B patients with inhibitors for:
1. Control and prevention of bleeding episodes
2. Use around the time of surgery
3. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
Instruction
Treatment should be initiated and supervised by a physician experienced in the management of haemophilia.
Drug interaction
No adequate and well-controlled studies of the combined or sequential use of FEIBA and recombinant Factor VIIa, antifibrinolytics, or emicizumab have been conducted.The possibility of thromboembolic events should be considered when systemic antifibrinolytics such as tranexamic acid and aminocaproic acid are used during treatment with FEIBA. Therefore, antifibrinolytics and FEIBA should be administered at least 6 hours apart.In cases of concomitant rFVIIa use, according to available in vitro data and clinical observations a potential drug interaction may occur (potentially resulting in adverse events such as a thromboembolic event).
Malaysia
